Originally published by our sister publication Specialty Pharmacy Continuum
By SPC Staff
The FDA expanded the indication for the calcitonin gene–related peptide receptor antagonist atogepant (Qulipta, AbbVie) for the preventive treatment of migraine in adults. The drug, which was previously approved for episodic migraine, is now also approved for chronic migraine (headaches for 15 or more days per month, at least eight of which are associated with migraine).
The FDA’s decision